| Bioactivity | TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases[1]. |
| In Vivo | 在豚鼠中，TAK-029（30-100 μg/kg，静脉注射）可完全抑制 ADP 诱导的体外血小板聚集，并延长给药后的 BT[1]。在狗中，TAK-029（30-100 μg/kg，静脉注射）可抑制 ADP 诱导的体外血小板聚集[1]。在猴子中，TAK-029（10-30 μg/kg，静脉注射）可抑制 ADP 诱导的体外血小板聚集，并延长 BT[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 176655-58-6 |
| Formula | C19H23N5O7 |
| Molar Mass | 433.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kawamura M, et al. Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys. Thromb Res. 1997 May 15;86(4):275-85. |